http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Applied DNA Enters into Supply Agreement with ITW Pillar Technologies to Bring CertainT® Platform to Textiles Including Those Used in Personal Protective Equipment
-
Applied DNA and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate
-
Applied DNA to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 15
-
Applied DNA Provides Update on Status of New York State Laboratory Permit for Clinical Labs Subsidiary
-
Applied DNA Positions LinearDNA™ Platform as the Next Generation Manufacturing Platform for Adeno-Associated Virus-based Gene Therapies Through New Patent Filing
-
Applied DNA Sciences (APDN) Receives Notice of Allowance on Second Patent Protecting Proprietary DNA Transfer System for Large-Scale Cotton Tagging
-
Applied DNA Receives Notice of Allowance on Second Patent Protecting Proprietary DNA Transfer System for Large-Scale Cotton Tagging
-
Applied DNA Reports Fiscal Third Quarter 2020 Financial Results
-
Applied DNA Sciences (APDN) Announces FDA Approves EUA Amendment Increasing COVID-19 Diagnostic Kit Testing Capacity
-
FDA Approves EUA Amendment Increasing Applied DNA’s COVID-19 Diagnostic Kit Testing Capacity Through Use of Automated RNA Extraction and Expands Supported Platforms
-
Applied DNA to Report Fiscal 2020 Third Quarter Financial Results After Market Close on August 6, 2020
-
Pre-Open Movers 07/17: (APDN) (OCN) (HMHC) Higher; (NIO) (NFLX) (ROKU) Lower (more...)
-
Applied DNA Sciences (APDN), Takis Biotech Announce Positive Preclinical Results from LineaDNA Vaccine Candidates for COVID-19
-
Applied DNA and Takis Report Positive Preclinical Results from LineaDNA™ Vaccine Candidates for COVID-19
-
Applied DNA Appoints New Head of Investor Relations and Corporate Communications
-
Applied DNA Sciences (APDN) Reports Formation of Clinical Testing Subsidiary to Maximize Utility of FDA EUA-Approved Linea COVID-19 Assay Kit
-
Applied DNA Forms Clinical Testing Subsidiary to Maximize Utility of FDA EUA-Approved Linea™ COVID-19 Assay Kit and Expands Utility with Successful EUA Amendment
-
Applied DNA Sciences Set to Join Russell Microcap Index
-
Applied DNA Sciences (APDN) Announces Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates
-
Applied DNA Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates
-
Applied DNA Sciences (APDN) Provides Update on Linear-DNA COVID-19 Vaccine Candidates Development Program
-
Applied DNA Provides Update on Linear-DNA COVID-19 Vaccine Candidates Development Program
-
Applied DNA to Participate in Maxim Group’s COVID-19 Virtual Conference Series on May 27
-
Applied DNA Reports 2020 Fiscal Second Quarter Financial Results
-
Applied DNA Sciences (APDN) Granted FDA Emergency Use Authorization for COVID-19 Diagnostic Assay Kit
-
Applied DNA Receives FDA Emergency Use Authorization for COVID-19 Diagnostic Assay Kit
-
Applied DNA Schedules Fiscal 2020 Second Quarter Financial Results Conference Call for Thursday, May 14, 2020 at 4:30 PM ET
-
Applied DNA Receives Approximately $5.3 Million in Net Proceeds from Warrant Exercise
-
Applied DNA Sciences (APDN) Applies to U.S. FDA for Emergency Use Authorization for COVID-19 Diagnostic Kit
-
Applied DNA Applies to U.S. FDA for Emergency Use Authorization for COVID-19 Diagnostic Kit
-
Applied DNA Sciences (APDN) Gains as Covid-19 Vaccine Shows Neutralizing Antibodies in Animals
-
Applied DNA and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals
-
Applied DNA Sciences (APDN) announces ETT of FDA has accepted Company into its Emerging Technology Program for molecular tagging
-
Applied DNA Accepted Into U.S. FDA’s Emerging Technology Program, Creating Pathway for Molecular Tagging of Pharmaceuticals and Packaging
-
Applied DNA High-Sensitivity and High-Throughput COVID-19 Diagnostic Kit Enters Validation Process in Partnership with Stony Brook University Hospital
-
Applied DNA Ships COVID-19 LinearDNA™ Vaccine Candidates to Italian Development Partner to Begin Preclinical Animal Testing
-
Applied DNA to Speak on COVID-19 Panel at Maxim Group’s Infectious Disease Virtual Conference on May 5
-
Applied DNA Sciences (APDN) and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate
-
Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate
-
Applied DNA Ships LinearDNA™ to Another Development Customer
-
Applied DNA Sciences (APDN) Files Provisional Patent Application for High Sensitivity COVID-19 Diagnostic Assay with USPTO
-
Applied DNA Files Provisional Patent Application for High Sensitivity COVID-19 Diagnostic Assay with U.S. Patent and Trademark Office
-
Applied DNA Secures Global Top-20 Pharmaceutical Manufacturer as Drug Development Customer
-
Applied DNA Sciences (APDN) Leverages COVID-19 Vaccine Development and Proprietary Linear DNA Manufacturing Capability to Design High Sensitivity Diagnostic Kit for Virus Detection
-
Applied DNA Leverages COVID-19 Vaccine Development and Proprietary Linear DNA Manufacturing Capability to Design a High Sensitivity Diagnostic Kit for Virus Detection
-
Applied DNA Sciences (APDN) Confirms COVID-19 Collaboration Partner Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of Vaccine Candidate on Pre-clinical Models
-
Applied DNA COVID-19 Collaboration Partner Takis Biotech Receives Italy Ministry of Health Approval to Begin Testing of a Vaccine Candidate on Pre-clinical Models
-
Pre-Open Stock Movers 03/02: (FTSV) (TRIL) (TWTR) Higher; (BIOC) (ENLV) (NVAX) Lower (more...)
-
Applied DNA Sciences (APDN) Updates on COVID-19 Collaboration with Takis Biotech
-
Applied DNA Sciences Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed

